Predicting Circulating Human Metabolites: How Good Are We?

被引:83
|
作者
Anderson, Shelby [1 ]
Luffer-Atlas, Debra [1 ]
Knadler, Mary Pat [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Dept Drug Disposit, Indianapolis, IN 46285 USA
关键词
DRUG METABOLITES; MASS-SPECTROMETRY; SAFETY ASSESSMENT;
D O I
10.1021/tx8004086
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The FDA issued a guidance on the safety testing of metabolites in February 2008, in which they stated that metabolites of concern are those that are detected at levels greater than 10% of the systemic exposure of the parent at steady state. This has presented many challenges in determining the circulating human metabolites at an early stage of development. The intention of this perspective is to address the question of how effective in vitro metabolism and early exploratory clinical data are in predicting the circulating metabolites from both a qualitative and a quantitative perspective. To this end, data were reviewed from 17 molecules in the Lilly portfolio for which there were in vitro data and a radiolabeled study in humans. Twelve example cases are presented in detail to demonstrate trends for when in vitro data adequately predicted in vivo (41%), when in vitro data underpredicted the circulating metabolites (35%), and when in vitro data overpredicted the circulating metabolites (24%). In addition, cases that present special challenges due to very low levels of the circulating parent or long half-lives of the parent and/or metabolites are presented. The trends indicate that the more complex the metabolism, the less likely the in vitro data were to predict the circulating metabolites. The in vitro data were also less predictive for N-glucuronidations and non-P450-mediated cleavage reactions. Although the in vitro data were better at predicting clearance pathways, the data set often failed to predict the quantity of metabolites, which is needed in consideration of whether or not a "disproportionate" metabolite may be circulating in human plasma.
引用
收藏
页码:243 / 256
页数:14
相关论文
共 50 条
  • [1] How good are we at predicting
    不详
    PAPERI JA PUU-PAPER AND TIMBER, 2003, 85 (07): : 385 - 385
  • [2] How good are we at predicting the individual response to personalized diets?
    de Roos, Baukje
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2024, 120 (01): : 3 - 4
  • [3] How good are we at predicting the fate of someone with acute myeloid leukaemia?
    E Estey
    R P Gale
    Leukemia, 2017, 31 : 1255 - 1258
  • [4] How good are we at predicting the fate of someone with acute myeloid leukaemia?
    Estey, E.
    Gale, R. P.
    LEUKEMIA, 2017, 31 (06) : 1255 - 1258
  • [5] How good are we?
    Hancock, WS
    JOURNAL OF PROTEOME RESEARCH, 2003, 2 (02) : 121 - 121
  • [6] Assessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites
    Kamimura, Hidetaka
    Nakada, Naoyuki
    Suzuki, Katsuhiro
    Mera, Ayako
    Souda, Kinya
    Murakami, Yuichi
    Tanaka, Kohichiro
    Iwatsubo, Takafumi
    Kawamura, Akio
    Usui, Takashi
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (03) : 223 - 235
  • [7] How Good We Had It
    Pollitt, Katha
    NATION, 2017, 304 (01) : 12 - 12
  • [8] Diagnosing melanoma: how do we assess how good we are?
    Esdaile, B.
    Mahmud, I.
    Palmer, A.
    Bowling, J.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (02) : 129 - 134
  • [9] UTILITY OF COMMON IN VITRO SYSTEMS FOR PREDICTING CIRCULATING METABOLITES
    Freiberger, Elyse
    Thompson, Michael
    Zhang, Xiaomei
    Underwood, Essence
    Lynch, Thomas
    Jenkins, Gary
    Wagner, David
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [10] Utility of Common In Vitro Systems for Predicting Circulating Metabolites
    Freiberger, Elyse C.
    Thompson, Michael P.
    Zhang, Xiaomei
    Underwood, Essence B.
    Lynch, Thomas L.
    Jenkins, Gary J.
    Wagner, David S.
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (12) : 1373 - 1378